Vaximm (Switzerland) a preclinical-stage biopharmaceutical company focused on therapeutic vaccines for various solid tumors, closed a $8M Series B financing. Participants include BB Biotech Ventures, Sunstone Capital, Merck Serono Ventures and BioMedPartners.